GW Pharmaceuticals Announces Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy From Physician-Led Expanded Access Treatment Program

Data Show Promising Signals of Efficacy and Safety -- Conference Call Today at 8:30 a.m. ET, 1:30 p.m. (UK)

LONDON, June 17, 2014 -- GW Pharmaceuticals plc (GWPH) (GWP.L) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced physician reports of efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with GW's investigational cannabidiol (CBD) product candidate, Epidiolex(R), for a period of 12 weeks.

European Medicines Agency Accepts HETLIOZ™ (tasimelteon) Marketing Authorization Application for Non-24-Hour Sleep-Wake Disorder in the Totally Blind

WASHINGTON, June 3, 2014 -- Vanda Pharmaceuticals Inc. (Vanda) (VNDA) announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

"The EMA submission is an important milestone towards providing a treatment option for people living with Non-24 in the European Union," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. "This continues our efforts to expand the availability of HETLIOZ to markets outside the U.S."

BioSyent Releases First Quarter 2014 Results-Sales Increase 59%, Net Income After Tax Up 49%

TORONTO, ONTARIO-- May 16, 2014) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its First Quarter (Q1 2014) financial results. Key highlights include:

• Q1 2014 Sales of $2,448,101 increased by 59% versus Q1 2013
• Q1 2014 Revenue has grown at a compound annual growth rate (CAGR) of 65% over the corresponding quarters of the last three years
• Q1 2014 Pharmaceutical Sales of $2,343,008 were up 79% versus Q1 2013
• Eighteen consecutive quarters of continued pharmaceutical sales growth
• Repeat orders for FeraMAX® 150 international customer
• Net Income Before Tax of $687,672 increased by 43% in Q1 2014 versus Q1 2013
• Q1 2014 Net Income After Tax of $511,421 increased by 49% versus Q1 2013

PERNIX Signs Agreement to Acquire TREXIMET® Tablets for Migraine From GSK

MORRISTOWN, N.J. -- Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that it has signed an agreement with GlaxoSmithKline (GSK) to acquire the U.S rights to Treximet^® (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults. Pernix’s team of approximately 90 specialty sales professionals will support the sales and marketing of Treximet^®.